- Stevanato Group has expanded its Bad Oeynhausen, Germany, facility with over 2,500 m² of state-of-the-art manufacturing space for drug delivery devices, including ISO 8 cleanrooms.
- The expansion supports both proprietary device production and contract manufacturing, increasing operational flexibility and speed-to-market for autoinjector and pen injector platforms.
Stevanato Group S.p.A., a global provider of drug containment, drug delivery, and diagnostic solutions, has announced a major expansion of its manufacturing capacity for drug delivery systems in Bad Oeynhausen, northern Germany. The initiative adds more than 2,500 square meters of production space designed to strengthen the company’s European supply-chain capabilities.
The expansion includes an ISO 8 cleanroom environment fully equipped for injection molding and automated assembly operations. It will support both Stevanato Group’s proprietary device production and contract manufacturing services, improving operational flexibility, scalability, and speed-to-market for its drug delivery portfolio.
Key devices benefiting from the enhanced facility include the Aidaptus® autoinjector and Alina® pen injector platforms. The site integrates the company’s expertise in glass primary packaging, analytical services, and equipment manufacturing to deliver patient-centric combination products tailored to individual customer needs.
“This investment underscores our commitment to advancing self-injection technologies and supporting our customers in delivering better patient outcomes. He added that the expansion ensures readiness, agility, and innovation across the value chain as demand for drug delivery devices continues to rise.”
Michele Monico, President of DDS and IVD Business Unit at Stevanato Group
The upgraded Bad Oeynhausen facility reinforces Stevanato Group’s role as a CDMO partner and manufacturer of combination products, providing global pharmaceutical and biotech companies with robust, scalable, and reliable drug delivery solutions.
